Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Sep
1
2015
FDA’s New Four-Letter Guidance on Biosimilars Mintz
Oct
11
2019
Do You Want Fries With That? Mintz
Sep
17
2015
Senators to Receive Update on Biosimilar Implementation from CDER’s Woodcock Mintz
Nov
23
2015
Congressional Hearing Examines Competition in PBM Industry Mintz
Jan
27
2020
Recap of Our Health Law and Policy Year-in-Review Posts for 2019 Mintz
Mar
2
2016
Kyle Bass’ Another Three IPRs: Targeting Anacor Mintz
Jun
28
2023
FDA Opens a Pilot Program to Scrutinize Certain Laboratory Developed Tests, But Will It Generate Sufficient Interest? Mintz
Mar
11
2020
FDA Gives a CBD Update: Spoiler Alert! It’s More or Less the Same Old News Mintz
Jun
7
2016
Pharmacy Summit White Paper Highlights Drug Development Process Mintz
Sep
20
2023
Mintz IRA Update — A Deeper Dive into Other Controversies of the IRA’s Medicare Drug Price Negotiation Program Mintz
Oct
24
2023
Telehealth Update: DEA Extends Flexibility in Prescribing Controlled Substances via Telehealth Through 2024 Mintz
Dec
19
2016
FDA Genetically Modified Food Review: “Extra Sweet Pink Flesh Pineapple” – Oh My! Mintz
Jan
12
2017
Supreme Court Declines to Revisit Broad Personal Jurisdiction Over ANDA Filers Mintz
Aug
20
2020
With Release of New Guidance, FDA Signals It’s Serious About Enforcing Clinical Trial Data Requirements Mintz
May
31
2017
FDA Commissioner Hints at Drug Pricing-Related Initiatives Mintz
Jan
18
2021
340B Administrative Dispute Resolution Goes Live Amid a Flurry of 340B Litigation Mintz
Apr
8
2021
FDA’s Biologics Inspections in the (Negative) Limelight: Will Congress or Executive Leadership Take Action? Mintz
Jan
11
2018
A Federal Court Gets Opportunity to Weigh In on Prop 65 With a Little Help from Some Friends Mintz
Aug
20
2012
Energy and Environment Law Update August 20, 2012 Mintz
Feb
1
2018
A Guide to New Jersey’s New Limits on Pharmaceutical Industry Payments to Prescribers Mintz
Apr
6
2013
Predictions of Single-Issue Energy Legislation, Hydraulic Fracturing, and American Energy Independence Mintz
Apr
13
2018
Report Details Uneven Implementation of the New Drug Tracing Law Mintz
Jun
22
2021
Get Ready for New York City’s New Biometric Identifier Information Law Mintz
Jul
3
2013
Energy and Environmental Law Update - Week of July 1, 2013 Mintz
Jul
16
2013
Energy and Environment Law Update - July 15, 2013 Mintz
Aug
20
2013
Energy and Environment Law Update - August 19, 2013 Mintz
Oct
20
2021
Coverage of FDA’s AI/ML Medical Devices Workshop - Part 3: A Summary of the Panel Discussions Mintz
Feb
11
2014
Energy and Environmental Law Update - February 10, 2014 Mintz
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins